Treatment of Alzheimers disease based on new drugs

Abstract

It is well-known that Alzheimers disease (AD) is a chronic neurodegeneration characterized by memory impairment, cognitive complexity, language impairment, mood swings, and behavioral abnormalities. The AD is related to a variety of factors and has been associated with circumstances, genes, generations and genders. The mechanism of pathogenesis is also unclear, and there are several hypothesis theories. The more convincing one is the deposition of amyloid. Although there is no one drug that can cure the AD completely, there are approved drugs that alleviate the development of the AD by preventing the breakdown of acetylcholinesterase and increasing the nerve cells that transmit messages. The development of new drugs and their use in the treatment of AD has received increasing attention. In this research, six drugs will be focused on, which are aduhelm, aricept, exelon, leqembi, namenda, and namzaric. Compared with single-target drugs, multi-target drugs can target different physiological aspects of the disease and have the advantages of fewer adverse effects, lower clinical doses and significant efficacy. Because their therapeutic mechanisms are different, patients can select the most appropriate drugs for different conditions of the AD according to the symptoms of the disease. Based on the current treatments, there is no way to cure the AD, hoping people could find a full cure for AD in the future.